EGFR and non-small cell lung carcinoma: For example, many randomized, open-label, phase III clinical trials have compared the effectiveness of EGFR tyrosine kinase inhibitors (EGFR-TKIs) with routine chemotherapy on NSCLC patients with mutated EGFR.